DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling

Investigational New Drugs

Volumn 28, Issue 6, 2010, Pages 783-790

  Liu, Moyan ^a   Fu, Lili ^a   Liu, Chunyan ^a   Xiong, Xishan ^a   Gao, Xiang ^a   Xiao, Min ^a   Cai, Houan ^a   Hu, Huimin ^a   Wang, Xueqi ^a   Mei, Changlin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

aryloxy methylhydrocinnamic acid derivative; catenin; ADPKD; GSK3 ; PPAR

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; BETA CATENIN; DH 9; GLYCOGEN SYNTHASE KINASE 3BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOCALIZATION; KIDNEY POLYCYSTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; UBIQUITINATION;

ANIMALS; APOPTOSIS; BETA CATENIN; CELL LINE; CELL PROLIFERATION; CINNAMATES; EPITHELIAL CELLS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; KIDNEY; MICE; PHENYLPROPIONATES; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PPAR GAMMA; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIMIDINES; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC;

EID: 78549286668     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9313-x     Document Type: Article

References (24)

1. FS Chou PS Wang S Kulp JJ Pinzone 2007 Effects of thiazolidinediones on differentiation, proliferation, and apoptosis Mol Cancer Res 5 523 530 1:CAS:528:DC%2BD2sXmsF2ns7w%3D 10.1158/1541-7786.MCR-06-0278 17579114 (Pubitemid 46985043)
2. CW Shiau CC Yang SK Kulp KF Chen CS Chen JW Huang 2005 Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma Cancer Res 65 1561 1569 1:CAS:528:DC%2BD2MXhsFKqtbo%3D 10.1158/0008-5472.CAN-04-1677 15735046 (Pubitemid 40270186)
3. S Han J Roman 2006 Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways Mol Cancer Ther 5 430 437 1:CAS:528:DC%2BD28XhvVelsbw%3D 10.1158/1535-7163.MCT-05- 0347 16505118
4. SE Nissen K Wolski 2007 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457 2471 1:CAS:528:DC%2BD2sXms1SisrY%3D 10.1056/NEJMoa072761 17517853
5. GA Diamond S Kaul 2007 Rosiglitazone and cardiovascular risk N Engl J Med 357 938 939 1:CAS:528:DC%2BD2sXpvVyktb4%3D 17806135
6. DM Nathan 2007 Rosiglitazone and cardiotoxicity-weighing the evidence N Engl J Med 357 64 66 1:CAS:528:DC%2BD2sXnsVynsr4%3D 10.1056/NEJMe078117 17551161 (Pubitemid 47026738)
7. BM Psaty CD Furberg 2007 The record on rosiglitazone and the risk of myocardial infarction N Engl J Med 357 67 69 1:CAS:528:DC%2BD2sXnsVynsr8%3D 10.1056/NEJMe078116 17551162 (Pubitemid 47026739)
8. Xiong X, Wang L, Ye Y, Fu L, Chen M, Wang Q, Liu M, Tang J, Dai B, Shen J, Mei C (2009) Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents. Invest New Drugs [Epub ahead of print]
9. JJ Grantham 2000 Time to treat polycystic kidney diseases like the neoplastic disorders that they are Kidney Int 57 339 340 1:STN:280: DC%2BD3c%2FoslWmug%3D%3D 10.1046/j.1523-1755.2000.00849.x 10620217 (Pubitemid 30227783)
10. E Kim T Arnould LK Sellin T Benzing MJ Fan W Grüning SY Sokol I Drummond G Walz 1999 The polycystic kidney disease 1 gene product modulates Wnt signaling J Biol Chem 274 4947 4953 1:CAS:528:DyaK1MXhsFSlsL4%3D 10.1074/jbc.274.8.4947 9988738 (Pubitemid 29113398)
11. T Roitbak CJ Ward C Peter A Harris 2004 Polycystin-1 multiprotein complex is disrupted in polycystic kidney disease cells Mol Biol Cell 15 1334 1346 1:CAS:528:DC%2BD2cXitlGgs7g%3D 10.1091/mbc.E03-05-0296 14718571 (Pubitemid 38316239)
12. ML Johnson N Rajamannan 2006 Diseases of Wnt signaling Rev Endocr Metab Disord. 7 41 49 1:CAS:528:DC%2BD2sXht12mtw%3D%3D 10.1007/s11154-006-9003-3 16944325 (Pubitemid 46044348)
13. S Saadi-Kheddouci D Berrebi B Romagnolo F Cluzeaud M Peuchmaur A Kahn A Vandewalle C Perret 2001 Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the β-catenin gene Oncogene 20 5972 5981 1:CAS:528:DC%2BD3MXnsVCjsL4%3D 10.1038/sj.onc.1204825 11593404 (Pubitemid 32955039)
14. AL Amand MW Klymkowsky 2001 Cadherins and catenins, Wnts and SOXs: embryonic patterning in Xenopus Int Rev Cytol 203 291 355 10.1016/S0074-7696(01) 03010-8
15. H Luu Hue Z Ruiwen, et al. 2004 Wnt/β-Catenin signaling pathway as novel cancer drug targets Current Cancer Drug Targets 4 653 671 1:STN:280:DC%2BD2cngsFKisA%3D%3D 10.2174/1568009043332709 15578921 (Pubitemid 40013572)
16. S Wei LF Lin CC Yang YC Wang GD Chang H Chen CS Chen 2007 Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma Mol Pharmacol 72 725 733 1:CAS:528:DC%2BD2sXhtVSgu77J 10.1124/mol.107. 035287 17569795 (Pubitemid 47347307)
17. S Han J Roman 2007 Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics? Anticancer Drugs 18 237 244 1:CAS:528:DC%2BD2sXhtVGis7c%3D 10.1097/CAD.0b013e328011e67d 17264754 (Pubitemid 46192975)
18. MR Smith PW Kantoff 2002 Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer Invest New Drugs 20 195 200 1:CAS:528:DC%2BD38XkvFersrg%3D 10.1023/A:1015670126203 12099579 (Pubitemid 34632654)
19. K Willert KA Jones 2006 Wnt signaling: is the party in the nucleus? Genes & Dev 20 1394 1404 1:CAS:528:DC%2BD28XlsF2ktL8%3D 10.1101/gad.1424006 (Pubitemid 43830647)
20. M Lal X Song JL Pluznick V Di Giovanni DM Merrick ND Rosenblum V Chauvet CJ Gottardi Y Pei MJ Caplan 2008 Polycystin-1 C-terminal tail associates with beta-catenin and inhibits canonical Wnt signaling Hum Mol Genet 17 3105 3117 1:CAS:528:DC%2BD1cXht1SitrrI 10.1093/hmg/ddn208 18632682
21. M Hart JP Concordet I Lassot I Albert R del los Santos H Durand C Perret B Rubinfeld F Margottin R Benarous P Polakis 1999 The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell Curr Biol 9 207 210 1:CAS:528:DyaK1MXhsFyrsbo%3D 10.1016/S0960-9822(99) 80091-8 10074433 (Pubitemid 29120385)
22. C Liu Y Li M Semenov C Han GH Baeg Y Tan Z Zhang X Lin X He 2002 Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism Cell 108 837 847 1:CAS:528:DC%2BD38XisFOgs70%3D 10.1016/S0092-8674(02)00685-2 11955436 (Pubitemid 34327534)
23. S Yu K Hackmann J Gao X He K Piontek GG Germino 2007 Essential role of cleavage of Polycystin-1 at G protein-coupled receptor proteolytic site for kidney tubular structure Proc Natl Acad Sci USA 104 18688 18693 1:CAS:528:DC%2BD2sXhtl2msrfO 10.1073/pnas.0708217104 18003909 (Pubitemid 350210758)
24. Loghman-Adham M, Nauli SM, Soto CE, Kariuki B, Zhou J (2003) Immortalized epithelial cells from human autosomal dominant polycystic kidney cysts. Am J Physiol Renal Physiol 283:397-412